Table 3.
Baseline characteristics of the longitudinal cohort
| Group | HF long (n = 7) | HTx long (n = 7) | P-value |
|---|---|---|---|
| Age at time of respective study (years) | 47 ± 19 | 48 ± 19 | NA |
| Gender n (%) | |||
| Male | 5 (71%) | Same | NA |
| Female | 2 (29%) | ||
| BMI (kg/m2) | 23.4 ± 3.3 | 26.4 ± 4.9 | <0.009 |
| Diabetes n (%) | 2 (29%) | 2 (29%) | NA |
| Weight gain since HTx (kg) | NA | 9.6 ± 6.2 | NA |
| Time since HTx (months) | NA | 7.4 ± 4.4 | NA |
| Aetiology | |||
| Ischaemic | 1 (14%) | Same | NA |
| Dilated | 5 (71%) | ||
| Valvular | 1 (14%) | ||
| HF drug therapy | |||
| Loop diuretic | 7 (100%) | NA | NA |
| ACE-inhibitor | 7 (100%) | ||
| Beta-blocker | 3 (43%) | ||
| Inotropes | 5 (71%) | ||
| HTx drug therapy | |||
| Prednisone (mg) | NA | 6 ± 4 | NA |
| Cyclosporine A | 3 (43%) | ||
| Tacrolimus | 4 (57%) | ||
| Mycophenolate mofetil | 6 (86%) | ||
NA, not applicable.
Bold text denotes P ≤ 0.05.